Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy
Abstract
Objectives: SCN1A mutations were recently reported in several patients with severe myoclonic epilepsy in infancy (SMEI). The authors analyzed SCN1A mutations in 93 patients with SMEI and made genotype-phenotype correlation to clarify the role of this gene in the etiology of SMEI.
Methods: All patients fulfilled the criteria for SMEI. The authors analyzed all patients for SCN1A mutations using denaturing high performance liquid chromatography. If a patient’s chromatogram was abnormal, the authors sequenced the gene in the patient and both parents.
Results: SCN1A mutations were identified in 33 patients (35%). Most mutations were de novo, but were inherited in three patients. Parents carrying the inherited mutations had either no symptoms or a milder form of epilepsy. A greater frequency of unilateral motor seizures was the only clinical difference between patients with SCN1A mutations and those without. Truncating mutations were more frequently associated with such seizures than were missense mutations. The percentage of cases with family history of epilepsy was significantly higher in patients with SCN1A mutations.
Conclusions: Unilateral motor seizures may be a specific clinical characteristic of SMEI caused by SCN1A mutations. Ten percent of SCN1A mutations are inherited from an asymptomatic or mildly affected parent, suggesting that SMEI is genetically heterogeneous. The increased frequency of familial epilepsy indicates that other genetic factors may contribute to this disorder.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Dravet C. Les épilepsies graves de l’enfant. Vie Med . 1978; 8: 354–548.
2.
Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. Severe myoclonic epilepsy in infants. In: Roger J, Dravet C, Bureau M, Dreifus FE, Perret A, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence. 2nd edition. London: John Libbey, 1992: 75–102.
3.
Yakoub M, Dulac O, Jambaque I, Chiron C, Plouin P. Early diagnosis of severe myoclonic epilepsy in infancy. Brain Dev . 1992; 14: 299–303.
4.
Ogino T, Ohtsuka Y, Amano R, Yamatogi Y, Ohtahara S. An investigation on the borderland of severe myoclonic epilepsy in infancy. Jpn J Psychiatry Neurol . 1988; 42: 554–555.
5.
Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet . 2001; 68: 1327–1332.
6.
Sugawara T, Mazaki-Miyazaki E, Fukushima K, et al. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology . 2002; 58: 1122–1124.
7.
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia . 1989; 30: 389–399.
8.
Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet . 2000; 24: 343–345.
9.
Malacarne M, Madia M, Gennaro E, et al. Lack of SCN1A mutations in familial febrile seizures. Epilepsia . 2002; 43: 559–562.
10.
Dalla Bernardina B, Capovilla G, Gattoni MB, et al. Epilepsie myoclonique grave de la première année. Rev Electroencephalogr Neurophysiol Clin . 1982; 12: 21–25.
11.
Dulac O, Arthuis M. Epilepsie myoclonique sévère de l’enfant. Journées Parisiennes de pédiatrie. Paris: Flammarion, 1982.
12.
Benlounis A, Nabbout R, Feingold J, et al. Genetic predisposition to severe myoclonic epilepsy in infancy. Epilepsia . 2001; 42: 204–209.
13.
Wallace RH, Scheffer IE, Barnett S, et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet . 2001; 68: 859–865.
14.
Escayg A, Heils A, MacDonald BT, et al. A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus and prevalence of variants in patients with epilepsy. Am J Hum Genet . 2001; 68: 866–873.
15.
Wallace RH, Wang DW, Singh R, et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat Genet . 1998; 19: 366–370.
16.
Sugawara T, Tsurubuchi Y, Agarwala KL, et al. A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc Natl Acad Sci USA . 2001; 98: 6384–6389.
17.
Baulac S, Huberfeld G, Gourfinkel-An I, et al. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet . 2001; 28: 46–48.
18.
Wallace RH, Marini C, Petrou S, et al. Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet . 2001; 28: 49–52.
19.
Singh R, Andermann E, Whitehouse WP, et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+? Epilepsia . 2001; 42: 837–844.
20.
Spiegelman JI, Mindrinos MN, Oefner PJ. High-accuracy DNA sequence variation screening by DHPLC. Biotechniques . 2000; 29: 1084–1090
21.
Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: a review. Hum Mutat . 2001; 17: 439–474.
22.
Ohmori I, Ouchida M, Ohtsuka Y, Oka E, Shimizu K. Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy. Biochem Biophys Res Commun . 2002; 295: 17–23.
23.
Sarisjulis N, Gamboni B, Plouin P, et al. Diagnosing idiopathic/cryptogenic epilepsy syndromes in infancy. Arch Dis Child . 2000; 82: 226–230.
24.
Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet . 2000; 356: 1638–1642.
25.
N’Guyen T, Chiron C, Dellatolas G, et al. Efficacité et tolérance à long terme du Stiripentol dans le traitement de l’épilepsie myoclonique sévère du nourrisson (syndrome de Dravet). Arch Pediatr 2003 (in press).
26.
Abou-Khalil B, Ge Q, Desai R, et al. Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology . 2001; 57: 2265–2272.
27.
Fujiwara T, Nakamura H, Watanabe M, et al. Clinicoelectrographic concordance between monozygotic twins with severe myoclonic epilepsy in infancy. Epilepsia . 1990; 31: 281–286.
28.
Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain . 1997; 120: 479–490.
29.
Hurst DL. Severe myoclonic epilepsy of infancy. Pediatr Neurol . 1987; 3: 269–272.
30.
Veggiotti P, Cardinali S, Montalenti E, et al. Generalized epilepsy with febrile seizures plus and severe myoclonic epilepsy in infancy: a case report of two Italian families. Epileptic Disord . 2001; 3: 29–32.
31.
Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc . 1996; 71: 576–586.
32.
Harkin LA, Bowser DN, Dibbens LM, et al. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet . 2002; 70: 530–536.
Information & Authors
Information
Published In
Copyright
© 2003.
Publication History
Received: September 17, 2002
Accepted: March 9, 2003
Published online: June 24, 2003
Published in print: June 24, 2003
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Voltage-gated sodium channel epilepsies in a tertiary care center: Phenotypic spectrum with correlation to predicted functional effects, Epilepsy & Behavior, 158, (109930), (2024).https://doi.org/10.1016/j.yebeh.2024.109930
- Evaluation of burden of SCN1A pathogenicity in North Indian children with Dravet syndrome, Seizure: European Journal of Epilepsy, 122, (10-18), (2024).https://doi.org/10.1016/j.seizure.2024.09.004
- Developing AAV-delivered nonsense suppressor tRNAs for neurological disorders, Neurotherapeutics, 21, 4, (e00391), (2024).https://doi.org/10.1016/j.neurot.2024.e00391
- Therapeutic potential of CBD in Autism Spectrum Disorder, Cannabidiol in Neurology and Psychiatry, (149-203), (2024).https://doi.org/10.1016/bs.irn.2024.05.002
- Fine mapping and candidate gene analysis of Dravet syndrome modifier loci on mouse chromosomes 7 and 8, Mammalian Genome, 35, 3, (334-345), (2024).https://doi.org/10.1007/s00335-024-10046-3
- Clocking Epilepsies: A Chronomodulated Strategy-Based Therapy for Rhythmic Seizures, International Journal of Molecular Sciences, 24, 4, (4223), (2023).https://doi.org/10.3390/ijms24044223
- Whole-Exome Sequencing Identifies Novel SCN1A and CACNB4 Genes Mutations in the Cohort of Saudi Patients With Epilepsy, Frontiers in Pediatrics, 10, (2022).https://doi.org/10.3389/fped.2022.919996
- Phenotypic and Genotypic Characteristics of SCN1A Associated Seizure Diseases, Frontiers in Molecular Neuroscience, 15, (2022).https://doi.org/10.3389/fnmol.2022.821012
- Critical Role of E1623 Residue in S3-S4 Loop of Nav1.1 Channel and Correlation Between Nature of Substitution and Functional Alteration, Frontiers in Molecular Neuroscience, 14, (2022).https://doi.org/10.3389/fnmol.2021.797628
- Role of SCN2A c.56G/A Gene Polymorphism in Egyptian Children with Genetic Epilepsy with Febrile Seizure Plus, CNS & Neurological Disorders - Drug Targets, 21, 5, (450-457), (2022).https://doi.org/10.2174/1871527320666211004123731
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.